SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system (CNS) disorders, today announced the appointment ofDavid C. Furlano, Ph.D., as Vice President, Regulatory Affairs.
"Dr. David Furlano brings to ACADIA more than 15 years of regulatoryaffairs experience. His broad experience of leading regulatory efforts forearly and late-stage drug candidates, marketed products, and acrosstherapeutic areas, including CNS indications, will be a great asset as ourdiscovery and development pipeline continues to mature," said Uli Hacksell,Ph.D., Chief Executive Officer of ACADIA.
Dr. Furlano joins ACADIA from Vical, where he served as ExecutiveDirector, Regulatory Affairs and had managerial and strategic responsibilityfor all aspects of regulatory affairs. Prior to Vical, he was ExecutiveDirector, Regulatory Affairs and Compliance at Amylin Pharmaceuticals, wherehe led the U.S. regulatory affairs group. Dr. Furlano also has heldregulatory positions at Ligand Pharmaceuticals, Abbott Laboratories andParke-Davis Pharmaceuticals. Earlier in his career, he worked as a reviewerat the U.S. Food and Drug Administration and as a research scientist at theNational Institutes of Health. Dr. Furlano received a Ph.D. degree inMedicinal Chemistry and Natural Products from the University of Iowa and aBachelor of Science degree from the University of Connecticut.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for CNSdisorders. ACADIA currently has four drug programs in clinical development aswell as a portfolio of preclinical and discovery assets directed at largeunmet medical needs, including schizophrenia, Parkinson's disease, neuropathicpain, and glaucoma. All of the drug candidates in ACADIA's product pipelineemanate from discoveries made using its proprietary drug discovery platform.ACADIA's corporate headquarters is located in San Diego, California and itmaintains research and development operations in both San Diego and Malmo,Sweden.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but are notlimited to statements related to the progress and timing of ACADIA's drugdiscovery and development programs and related trials. These statements areonly predictions based on current information and expectations and involve anumber of risks and uncertainties. Actual events or results may differmaterially from those projected in any of such statements due to variousfactors, including the risks and uncertainties inherent in drug discovery,development and commercialization, collaborations with others, and litigation.For a discussion of these and other factors, please refer to ACADIA's annualreport on Form 10-K for the year ended December 31, 2004 filed with the UnitedStates Securities and Exchange Commission as well as other subsequent filingswith the Securities and Exchange Commission. You are cautioned not to placeundue reliance on these forward-looking statements, which speak only as of thedate hereof. This caution is made under the safe harbor provisions of thePrivate Securities Litigation Reform Act of 1995. All forward-lookingstatements are qualified in their entirety by this cautionary statement andACADIA undertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof.
Contacts:
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
(858) 558-2871